MedTrace Logo

6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension

NCT05475886 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-02

No results posted yet for this study

Summary

The purpose of this study is to investigate the ED50 and ED90 for an effective 6% Hydroxyethyl starch (130/0.4) coload infusion dose for postspinal anesthesia hypotension in patients undergoing cesarean section.

Conditions

  • Adverse Effect

Interventions

DRUG

Hydroxyethyl starch 130/0.4

An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.

Sponsors & Collaborators

  • General Hospital of Ningxia Medical University

    lead OTHER

Principal Investigators

  • Yi Chen, M.D. · General Hospital of Ningxia Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-04-21
Completion
2024-04-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05475886 on ClinicalTrials.gov